When Unsuspected Crystallinity Ruins Biological Testing in Early Discovery: A Case Study

Claudi de Rocafiguera, Blanca Belsa, Mercè Font-Bardia, Cristina Puigjaner, Eduard Serra, Ana M. Cuartero-Albesa, Raimon Puig de la Bellacasa, José I. Borrell

Research output: Indexed journal article Articlepeer-review

Abstract

The impact of the crystalline or amorphous structure of a solid on the solubility and pharmacokinetic properties of a drug candidate is always considered by the pharmaceutical industry during the development of a new drug; however, it is not so frequently considered during the early drug discovery process by organic and medicinal chemists, particularly those working in academia. We want to share, as an example, the false negative obtained in the biological testing of a solid sample of a tyrosine kinase inhibitor due to its unexpected crystallinity and lower solubility with respect to a solid amorphous batch of the same compound and the experimentation carried out to establish the origin of such a discrepancy.

Original languageEnglish
Article number284
JournalPharmaceuticals
Volume17
Issue number3
DOIs
Publication statusPublished - Mar 2024

Keywords

  • biological activity
  • crystallinity
  • solubility

Fingerprint

Dive into the research topics of 'When Unsuspected Crystallinity Ruins Biological Testing in Early Discovery: A Case Study'. Together they form a unique fingerprint.

Cite this